Dr Lal PathLabs Ltd Stock Price Today (NSE: LALPATHLAB)
Fundamental Score
Dr Lal PathLabs Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Dr Lal PathLabs Ltd share price today is ₹1577.30, down 1.87% on NSE/BSE as of 1 June 2026. Dr Lal PathLabs Ltd (LALPATHLAB) is a Large-cap company in the Healthcare Service Provider sector with a market capitalisation of ₹25.56K (Cr). The 52-week high for LALPATHLAB share price is ₹3540.00 and the 52-week low is ₹1272.60. At a P/E ratio of 47.83x, LALPATHLAB is currently trading above its industry average P/E of 39.28x. The company has a Return on Equity (ROE) of 24.30% and a debt-to-equity ratio of 0.07.
Dr Lal PathLabs Ltd Share Price Chart — NSE/BSE Historical Performance
Dr Lal PathLabs Ltd share price chart: 14.15% return over the past month. 52-week high ₹3540.00, 52-week low ₹1272.60.
Dr Lal PathLabs Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1598.20 | ₹1636.80 | ₹1592.00 | ₹1617.20 | 2.03L (Cr) | |
| ₹1601.00 | ₹1639.00 | ₹1591.50 | ₹1604.00 | 4.62L (Cr) | |
| ₹1640.00 | ₹1651.50 | ₹1588.00 | ₹1614.90 | 1.98L (Cr) | |
| ₹1670.00 | ₹1680.80 | ₹1618.00 | ₹1630.10 | 1.94L (Cr) | |
| ₹1668.80 | ₹1717.10 | ₹1668.80 | ₹1680.80 | 1.77L (Cr) | |
| ₹1703.60 | ₹1707.00 | ₹1647.10 | ₹1668.60 | 2.22L (Cr) | |
| ₹1659.80 | ₹1719.90 | ₹1648.00 | ₹1703.70 | 5.40L (Cr) | |
| ₹1585.10 | ₹1649.50 | ₹1581.40 | ₹1646.30 | 4.83L (Cr) | |
| ₹1615.70 | ₹1639.90 | ₹1575.00 | ₹1602.90 | 5.54L (Cr) | |
| ₹1588.50 | ₹1609.60 | ₹1571.20 | ₹1600.10 | 2.59L (Cr) |
Dr Lal PathLabs Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹1390.40 | ₹1719.90 | ₹1390.00 | ₹1617.20 | +16.31% | |
| ₹1316.20 | ₹1471.50 | ₹1285.00 | ₹1367.20 | +3.87% | |
| ₹1361.00 | ₹1428.30 | ₹1272.60 | ₹1312.10 | -3.59% | |
| ₹1424.60 | ₹1474.00 | ₹1363.30 | ₹1399.90 | -1.73% | |
| ₹1483.30 | ₹1520.00 | ₹1345.20 | ₹1409.50 | -4.98% | |
| ₹3055.00 | ₹3069.20 | ₹1348.00 | ₹1482.60 | -51.47% | |
| ₹3154.90 | ₹3309.20 | ₹3024.40 | ₹3051.80 | -3.27% | |
| ₹3105.00 | ₹3235.00 | ₹3002.90 | ₹3135.50 | +0.98% | |
| ₹3308.80 | ₹3540.00 | ₹3102.00 | ₹3118.10 | -5.76% | |
| ₹3190.00 | ₹3506.40 | ₹3085.20 | ₹3308.90 | +3.73% | |
| ₹2818.80 | ₹3175.00 | ₹2742.80 | ₹3150.90 | +11.78% | |
| ₹2800.00 | ₹3029.70 | ₹2730.00 | ₹2796.30 | -0.13% |
AI Research Briefing
Powered by Gemini · 2026-04-09
Overvalued and facing margin pressure, Dr. Lal PathLabs is a risky bet despite expansion plans.
WHAT'S HAPPENING NOW (last 2-4 weeks)
Dr. Lal PathLabs is set to announce FY26 results on April 30, 2026, and the trading window is closed until May 2. In March 2026, the company issued a notice regarding the transfer of unclaimed equity shares to the IEPF. The board approved the acquisition of immovable property in New Delhi for in September 2025.
CORE STORY (THE REAL GAME)
Dr. Lal PathLabs is a diagnostics chain navigating the shift towards integrated wellness and technology-driven healthcare in India. The market is watching to see if they can maintain growth and margins amidst increasing competition and the need for continuous investment in technology and infrastructure.
- FY26 results due on April 30, 2026
- Seeking acquisitions in South India
- Completed Suburban Diagnostics liquidation
- Successful acquisition in South India
- Better-than-expected FY26 results
- Significant technological breakthrough
- High P/E ratio compared to industry average
- Intense competition in the diagnostics sector
- Integration risks with future acquisitions
FII decreased holdings from 21.86% to 20.29% in Dec 2025. DII have increased holdings from 18.49% to 19.20% in Dec 2025.
Healthcare in India is moving towards digital integration and preventive care.
Acquisition of immovable property in New Delhi for ₹74.51 crore approved in September 2025.
Yes - Free Cash Flow 5Y: ₹1717.61 Cr.
Focus on acquisitions in South India and technology integration. Success hinges on execution and margin management.
Primary Thesis Risk
Inability to maintain margins amidst competition and tech investments.
For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Dr Lal PathLabs Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Dr Lal PathLabs Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of LALPATHLAB across key market metrics for learning purposes.
Positive Indicators
12 factors identified
Strong Return on Equity (24.30%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (28.88%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (26.94%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Consistent Growth Track Record (13.09% CAGR)
Observation: Strong 5-year sales compound annual growth rate.
Analysis: Consistent sales CAGR >12% demonstrates sustainable growth model.
Excellent EPS Growth (16.63% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (16.69% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Conservative Debt Levels (D/E: 0.07)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (35.16x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹1717.61 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (53.21%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 40.08%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
1 factors identified
Premium Valuation Risk (P/E: 47.83x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Dr Lal PathLabs Ltd vs Healthcare Service Provider Peers
Peer Comparison - Healthcare Service Provider
Compare Dr Lal PathLabs Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Dr Lal PathLabs LtdDr Lal PathLabs...Selected✓ LALPATHLAB • 539524 | 64.3/100 | ₹1577.30₹1577 | ₹25557.40₹25557.40 | 47.83Average 47.8 Average | 24.30%Excellent 24.30% Excellent | 28.88%Excellent 28.88% Excellent | 0.07Excellent 0.1 Excellent | 16.69%Excellent 16.69% Excellent | 13.09%Good 13.09% Good | 0.79% |
Vijaya Diagnostic Centre LtdVijaya Diagnost... VIJAYA • 543350 | 53.7/100 | ₹1302.80₹1303 | ₹10272.45₹10272.45 | 67.39Average 67.4 Average | 19.00%Good 19.00% Good | 20.91%Excellent 20.91% Excellent | 0.42Excellent 0.4 Excellent | 18.97%Excellent 18.97% Excellent | 15.00%Excellent 15.00% Excellent | 0.20% |
Metropolis Healthcare LtdMetropolis Heal... METROPOLIS • 542650 | 48.9/100 | ₹508.40₹508 | ₹10124.28₹10124.28 | 63.98Average 64.0 Average | 11.53%Average 11.53% Average | 14.66%Average 14.66% Average | 0.14Excellent 0.1 Excellent | -0.56%Poor -0.56% Poor | 9.22%Good 9.22% Good | 0.20% |
Thyrocare Technologies LtdThyrocare Techn... THYROCARE • 539871 | 40.5/100 | ₹452.20₹452 | ₹7724.80₹7724.80 | 60.48Average 60.5 Average | 16.15%Good 16.15% Good | 24.78%Excellent 24.78% Excellent | 0.05Excellent 0.1 Excellent | -0.64%Poor -0.64% Poor | 9.62%Good 9.62% Good | 1.44% |
Krsnaa Diagnostics LtdKrsnaa Diagnost... KRSNAA • 543328 | 39.6/100 | ₹566.30₹566 | ₹2626.09₹2626.09 | 30.73Average 30.7 Average | 9.29%Poor 9.29% Poor | 12.52%Average 12.52% Average | 0.30Excellent 0.3 Excellent | 22.05%Excellent 22.05% Excellent | 21.41%Excellent 21.41% Excellent | 0.34% |
Suraksha Diagnostic LtdSuraksha Diagno... SURAKSHA • 544293 | 47.1/100 | ₹299.50₹300 | ₹1534.08₹1534.08 | 48.05Average 48.0 Average | 16.46%Good 16.46% Good | 17.84%Good 17.84% Good | 0.51Good 0.5 Good | 16.38%Excellent 16.38% Excellent | 9.86%Good 9.86% Good | 0.00% |
3B Blackbio Diagnostics Ltd3B Blackbio Dia... 3BBLACKBIO • 532067 | 66.1/100 | ₹1225.40₹1225 | ₹1080.56₹1080.56 | 22.01Average 22.0 Average | 19.40%Good 19.40% Good | 25.75%Excellent 25.75% Excellent | 0.00Excellent 0.0 Excellent | 44.03%Excellent 44.03% Excellent | 27.29%Excellent 27.29% Excellent | 0.32% |
One Global Service Provider IncOne Global Serv... ONEGLOBAL • 514330 | 69.5/100 | ₹437.90₹438 | ₹1070.08₹1070.08 | 24.39Average 24.4 Average | 42.31%Excellent 42.31% Excellent | 56.38%Excellent 56.38% Excellent | 0.00Excellent 0.0 Excellent | 128.82%Excellent 128.82% Excellent | — — | 0.00% |
Sastasundar Ventures LtdSastasundar Ven... SASTASUNDR • 533259 | 40.3/100 | ₹292.50₹293 | ₹1042.27₹1042.27 | — — | 4.63%Poor 4.63% Poor | -1.33%Poor -1.33% Poor | 0.01Excellent 0.0 Excellent | 23.31%Excellent 23.31% Excellent | 24.47%Excellent 24.47% Excellent | 0.00% |
46.5/100 | ₹233.90₹234 | ₹826.72₹826.72 | 30.47Average 30.5 Average | 27.08%Excellent 27.08% Excellent | 28.85%Excellent 28.85% Excellent | 0.48Excellent 0.5 Excellent | — — | — — | 0.00% | |
Choksi Imaging LtdChoksi Imaging ... CHOKSI • 526546 | 45.3/100 | ₹126.35₹126 | ₹92.81₹92.81 | 55.91Average 55.9 Average | 6.63%Poor 6.63% Poor | 9.20%Poor 9.20% Poor | 1.18Average 1.2 Average | 32.13%Excellent 32.13% Excellent | 8.21%Good 8.21% Good | 0.00% |
Top Healthcare Service Provider Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Vijaya Diagnostic Centre Ltd share price10272.45 Cr
- Metropolis Healthcare Ltd share price10124.28 Cr
- Thyrocare Technologies Ltd share price7724.80 Cr
- Krsnaa Diagnostics Ltd share price2626.09 Cr
- Suraksha Diagnostic Ltd share price1534.08 Cr
Dr Lal PathLabs Ltd PE Ratio History
Historical price-to-earnings ratio for LALPATHLAB — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹58.40 | ₹1482.60 | 25.4x |
| FY 2024 | ₹42.98 | ₹3000.40 | 69.8x |
| FY 2023 | ₹28.74 | ₹2577.70 | 89.7x |
| FY 2022 | ₹41.57 | ₹2260.45 | 54.4x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Dr Lal PathLabs Ltd Dividend History
Annual cash dividends paid by LALPATHLAB — dividend yield 0.79%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹207.30 Cr |
| FY 2024 | ₹201.17 Cr |
| FY 2023 | ₹103.01 Cr |
| FY 2022 | ₹116.70 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Dr Lal PathLabs Ltd Quarterly Performance
Latest quarterly metrics for LALPATHLAB — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
10.66%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
16.41%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
13.09%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
16.69%
Compounded annual net profit growth over 5 years
Dr Lal PathLabs Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for LALPATHLAB — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Dr Lal PathLabs Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Dr Lal PathLabs Ltd (LALPATHLAB) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Dr Lal PathLabs Ltd
About LALPATHLAB (Dr Lal PathLabs Ltd)
Dr Lal PathLabs Ltd is a prominent healthcare service provider specializing in diagnostic and related healthcare tests. With a long-standing reputation built over decades, the comp...any serves as a crucial bridge between medical professionals and patients, offering a comprehensive suite of diagnostic services. Their network encompasses a broad spectrum of tests, from routine blood work to sophisticated genetic and molecular analyses, all performed within state-of-the-art laboratory environments. Leveraging advanced technology and stringent quality control measures, Dr Lal PathLabs provides accurate and timely results that are essential for informed clinical decision-making, aiding in the diagnosis, treatment, and monitoring of various health conditions. The company's operational capabilities extend beyond conventional diagnostics, encompassing specialized testing in areas such as infectious diseases, oncology, and reproductive health. These advanced services cater to the increasing demand for personalized medicine and precision diagnostics, empowering clinicians with insights crucial for tailoring treatments to individual patient needs. Dr Lal PathLabs consistently invests in research and development to stay at the forefront of diagnostic innovation, ensuring that their test menu reflects the latest advancements in medical science. Moreover, their commitment to accessibility is reflected in a widespread network of collection centers, making diagnostic services readily available to a diverse population across geographical regions. Beyond their core testing services, Dr Lal PathLabs also contributes to healthcare advancement through training and educational initiatives. They offer programs aimed at enhancing the skills and knowledge of healthcare professionals, particularly in areas related to phlebotomy and laboratory techniques. This commitment to professional development strengthens the broader healthcare ecosystem, ensuring a skilled workforce capable of delivering high-quality diagnostic services. By combining cutting-edge technology, a comprehensive test menu, and a dedication to professional training, Dr Lal PathLabs plays a vital role in promoting health and well-being within the communities they serve.
Company Details
Key Leadership
Corporate Events
LALPATHLAB Share Price: Frequently Asked Questions
What is the current share price of Dr Lal PathLabs Ltd?
Dr Lal PathLabs Ltd (LALPATHLAB) trades at ₹1577.30 on NSE and BSE. Market cap ₹25.56K (Cr). Educational data only.
What is the P/E ratio of Dr Lal PathLabs Ltd?
Dr Lal PathLabs Ltd has a P/E of 47.83x vs industry average 39.28x.
What is the Bull Run score for Dr Lal PathLabs Ltd?
Dr Lal PathLabs Ltd has a Bull Run score of 64.3/100 based on 25+ financial parameters.
Does Dr Lal PathLabs Ltd pay dividends?
Dr Lal PathLabs Ltd has a dividend yield of 0.79%. Past dividends don't guarantee future payments.
What is the ROE of Dr Lal PathLabs Ltd?
Dr Lal PathLabs Ltd has ROE of 24.30%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Dr Lal PathLabs Ltd?
Dr Lal PathLabs Ltd has debt-to-equity of 0.07.
Is Dr Lal PathLabs Ltd a good investment?
Bull Run gives Dr Lal PathLabs Ltd a score of 64.3/100. This is not investment advice — consult a SEBI-registered advisor.